1. Introduction {#sec1}
===============

Discovering the role of the microbiota-gut-brain axis is one of the most important advances in the field of gastroenterology and psychology in the past decade ([@bib4]; [@bib13]; [@bib19]; [@bib53]). Gut bacteria have been found to participate in the regulation of various psychological processes, including mood, cognition, memory, social behavior, and brain development ([@bib18]; [@bib31]; [@bib56]; [@bib61]). These effects may be mediated via immune, nervous or neuroendocrine systems ([@bib6]; [@bib21]). The microbiota-gut-brain axis presents as a target for developing novel therapies for brain dysfunction, especially through dietary strategies, such as through the intake of probiotics and/or prebiotics ([@bib7]; [@bib33]; [@bib38]).

Depression, which is commonly comorbid with anxiety, is a heterogeneous neuropsychiatric disorder. The total number of people who are currently living with depression is more than 320 million worldwide ([@bib46]). The serotonin (5-hydroxytryptamine, 5-HT) system in the brain is key for both the development of depression and its treatment ([@bib12]). Although the first-line treatment for depression remains the selective serotonin reuptake inhibitor (SSRI), only a third of patients receive the emotional benefits ([@bib65]). Moreover, chronic SSRI treatment normally works after a delay of 2--4 weeks in conjunction with many reported side effects in the gastrointestinal tract (such as constipation) ([@bib39]; [@bib44]; [@bib45]). As the precursor of 5-HT, 5-hydroxytryptophan (5-HTP) is widely known for its capacity to cross the blood-brain barrier and to yield antidepressant-like function, now becoming the focus of medical and scientific interest ([@bib25]).

Animal studies have shown that the microbiome is sensitive to the effects of depression ([@bib3]; [@bib5]; [@bib20]; [@bib47]; [@bib50]). In recent years, emerging clinical data has revealed that the gut microbiota in major depression disorders (MDD) patients is also altered ([@bib24]; [@bib27]; [@bib30]; [@bib47]; [@bib62]). Besides, transplantation of fecal microbiota from depressed patients into microbiota-deficient rodents resulted in a transfer of the depressive phenotype ([@bib30]), identifying the essential role of the gut microbiota in the development of depression. Based on the understanding of the microbiota-brain-gut axis, several clinical studies are emerging showing the successful alleviation of depression or stress-related symptomatology with probiotics ([@bib28]; [@bib47]; [@bib66]). Exploration of the above studies opens new avenues for treating depression. However, the mechanisms are not well elucidated ([@bib17]; [@bib57]; [@bib59]).

Herein, we focused on the interaction between gut microbiota and enterochromaffin cells, using a specific strain of bacteria *Bifidobacterium breve* CCFM1025, which facilitates 5-HTP synthesis, to explore a novel therapeutic approach for curtailing depression ([@bib63]). We systematically investigated the impact of CCFM1025 on behaviors, brain neurophysiological alterations, immune status, neuroendocrine responses, as well as gut microbial composition, metabolite production, and functional gene expression.

2. Materials & methods {#sec2}
======================

2.1. Animal experiment {#sec2.1}
----------------------

Male adult C57BL/6 mice (6 weeks of age, purchased from SLAC Experimental Animal Co., Ltd, Shanghai, China) were used in the study. The mice were housed in an environmentally controlled (21°C--23 °C, 50%--60% of humidity) room under a 12:12h light-dark cycle with free access to food and water. Animals were allowed to adapt to the environment for one week prior to testing. Forty mice were randomly assigned into four groups (n = 10 in each group). All animal experiments were approved by the Experimental Animal Ethics Committee of Jiangnan University (qualified number: JN. No20181215c0480130 \[268\]). All procedures were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). The experimental schedule is shown in [Fig. 1](#fig1){ref-type="fig"}. Protocols of chronic unpredictable mild stress (CUMS) procedures and behavioral tests are described in Supplemental 1.1 and 1.2.Fig. 1Animal experimental schedule. The whole period is seven weeks, including one-week adaptation and six-week treatment. Behavioral tests were performed during the sixth week for all the mice.Fig. 1

2.2. Bacterial treatment {#sec2.2}
------------------------

The biological origin of *Bifidobacterium breve* CCFM1025 is described in Supplemental 1.3. The bacterium was cultured in MRS liquid medium (supplemented with 0.05% L-cysteine) and grown anaerobically at 37 °C. Bacteria for oral administration were prepared by suspending the lyophilized bacteria powder in 10% skimmed cow milk. Colony counting was done to aliquot the concentration of surviving bacteria at 10^9^ CFU/mL. The CCFM1025 treatment group was gavaged at a volume of 0.1 ml/10g body weight daily.

*2.3*. *In vitro* cellular experiment {#sec2.3}
-------------------------------------

The enterochromaffin cell experiment was carried out as previously described ([@bib63]; [@bib67]). Briefly, RIN14B cells (ATCC CRL-2059) were pre-treated with 0.1% BSA and 2 μM fluoxetine for 10 s, then cultured in Hank\'s balanced salt solution containing 10 μM short-chain fatty acids (SCFAs). The bacterial fermented supernatants were passed through 0.2 μm pore syringe filters before added to the cells. At the time point of 0, 15, 30 min, the cells were collected for additional real-time PCR measurement.

2.4. Quantitative real-time PCR (qRT-PCR) {#sec2.4}
-----------------------------------------

Briefly, RNA was extracted using Trizol reagent (Invitrogen, USA). Complementary DNA was prepared using the PrimeScript RT reagent Kit (Takara Bio Inc., Japan) according to the manufacturer\'s protocol. Quantitative PCR was carried out on a BioRad-CFX384 system using SYBR Green Supermix (Bio-Rad, USA). Amplification reactions were run with "no template" controls, all in triplicate, for each probe used. Cycle threshold (Ct) values were recorded and normalized to the *Gapdh* using the 2^−ΔΔCt^ method. Detailed procedures and primer sets are shown in [Supplemental Table S1](#appsec1){ref-type="sec"}.

2.5. Biochemical measurements {#sec2.5}
-----------------------------

5-HT and 5-HTP levels in tissues and serum were quantified by HPLC with fluorescence detection as described ([@bib64]). Brain-derived neurotrophic factor (BDNF), Corticotropin-releasing factor (CRF), corticosterone, and inflammatory cytokines (TNF-α, IL-β, IL-6, and IL-17) were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer\'s protocol (R&D Systems, USA). SCFAs were extracted by diethyl ether from fresh cecal contents and qualified on the TSQ 9000 GC-MS system (Thermo Scientific) as previously described ([@bib63]).

2.6. Western blotting {#sec2.6}
---------------------

A detailed procedure is shown in Supplemental 1.5. Primary antibodies used for detection are as follows: cAMP-response element-binding protein (CREB; 1:1000, Cell Signaling Technology, \#9197), phosphorylated-CREB (pCREB; Ser133, 1:1000, Cell Signaling Technology, \#9198), Tryptophan hydroxylases 1 (TPH1; 1:1000, ABclonal, A1569), and GAPDH (1:3000, ABclonal, AC033). The secondary antibody was horseradish peroxidase (HRP)-conjugated (1:5000, Goat anti-mouse/rabbit IgG-HRP, Absin, abs20001/20002). Protein bands were visualized by chemiluminescence using ECL luminescence reagent (Absin Bioscience Inc., Shanghai, China). Protein expression was quantified using ImageJ software and shown as density relative to GAPDH.

2.7. Immunostaining of brain sections {#sec2.7}
-------------------------------------

The detailed procedure is shown in Supplemental 1.6. Briefly, hippocampal sections were made and subjected to immunohistochemical (IHC) detection of proBDNF (1:100, Santa Cruz, sc-65514), and immunofluorescence (IF) detection of c-Fos (1: 200, Cell Signaling Technology, \#2250). Immunoreactivities were visualized using 3, 3′-diaminobenzidine-IHC- and fluorescein -IF-Detection Kit (Sangon Biotech, Shanghai, China) according to the manufacturer\'s instructions. Stained slides were digitized with a confocal laser scanning microscope system (ZEISS, Germany), and analyzed with Image-Pro Plus software (Media Cybernetics, USA) by pathologists blinded to the experimental parameters.

2.8. Metagenomic sequencing and bioinformatic analysis {#sec2.8}
------------------------------------------------------

The procedure of fecal 16S rRNA sequencing is described in detail in Supplemental 1.7. Quantitative Insights into Microbial Ecology (QIIME) platform was used to process the raw data of sequencing ([@bib9]). Operational taxonomic units (OTUs) were picked using a criterion of 97% nucleotide identity based on the Greengenes 13.5 database. α-Diversity was measured by species richness and evenness from the rarefied OTU and indicated as Shannon and Simpson index. β-Diversity was estimated by unweighted pairwise UniFrac distances, visualized with principal component analysis (PCA) and principal coordinate analysis (PCoA), and permutational multivariate analysis of variance (perMANOVA) was used to assess differences ([@bib16]; [@bib23]). Linear discriminant analysis (LDA) effect size (LEfSe) was used to differentiate microbial biomarkers (Wilcoxon rank-sum test, α \< 0.05 and logLDA\>3.0 were used as the threshold) and visualized by taxonomic cladogram tree (<http://huttenhower.org/galaxy>). Metagenomes of gut microbiota were computed from 16S rRNA sequences based on Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), predicted functional pathways were annotated from the Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology ([@bib35]). The network was constructed with Spearman\'s correlation coefficients and visualized by Gephi (V. 0.9.1). In all cases, recommended parameters were used, unless otherwise mentioned.

2.9. Statistical analysis {#sec2.9}
-------------------------

Statistical analysis was performed using Prism 6.0 software and SPSS 21.0. Data are presented as means with SEM. For data sets confirmed with a normal distribution (Shapiro-Wilk test), unpaired Student\'s t-test was performed between the Control and CUMS group, and one-way ANOVA was performed to compare the effects of Fluoxetine and CCFM1025 in CUMS-treated animals, followed by Dunnett\'s multiple comparisons test against the CUMS group. For data sets that were not normally distributed, the Mann Whitney test was performed between the Control and CUMS group, and the Kruskal-Wallis test was performed for the CUMS, Fluoxetine- and CCFM1025-treated groups with Dunn\'s post hoc test against the CUMS group. Effect size (Cohen\'s d) of all comparisons was shown in the [Supplemental Table S2-S6](#appsec1){ref-type="sec"}. A criterion for significance was set to *P* \< 0.05 in all comparisons. The *P*-value of multiple comparisons (*P*~*adj*~) was adjusted by family-wise significance and confidence levels of 0.05 (95% confidence interval).

3. Results {#sec3}
==========

3.1. CCFM1025 treatment decreased anxiety- and depressive-like behaviors {#sec3.1}
------------------------------------------------------------------------

Five-weeks of chronic stress induced significant depressive-like symptoms, including increased immobility ([Fig. 2](#fig2){ref-type="fig"}B, T ~(14)~ = 2.953, *P* = 0.011; [Fig. 2](#fig2){ref-type="fig"}C, T ~(16)~ = 3.424, *P* = 0.004), and anhedonia ([Fig. 2](#fig2){ref-type="fig"}E, T ~(14)~ = 3.240, *P* = 0.006). Anxiety-like symptoms were reflected by the reduced time spent in the center and open areas ([Fig. 2](#fig2){ref-type="fig"}A, T ~(18)~ = 5.270, *P* \< 0.001; [Fig. 2](#fig2){ref-type="fig"}D, T ~(16)~ = 2.879, *P* = 0.011). All behavioral abnormalities were reversed by CCFM1025 treatment ([Fig. 2](#fig2){ref-type="fig"}A, F ~(2,\ 25)~ = 14.880, *P*~*adj*~ \< 0.001; [Fig. 2](#fig2){ref-type="fig"}B, F ~(2,\ 20)~ = 6.909, *P*~*adj*~ = 0.005; [Fig. 2](#fig2){ref-type="fig"}C, F ~(2,\ 24)~ = 10.850, *P*~*adj*~ \< 0.001; [Fig. 2](#fig2){ref-type="fig"}D, F ~(2,\ 22)~ = 9.256, *P*~*adj*~ = 0.001; [Fig. 2](#fig2){ref-type="fig"}E and F ~(2,\ 21)~ = 4.148, *P*~*adj*~ = 0.03).Fig. 2The antidepressant-like and anxiolytic effect of CCFM1025. (A) Open-field test (n = 8--10). The panel displays a representative heatmap of tracking movement, and the histogram indicates time spent in the open area (percentage of the total time). (B) Tail suspension test (n = 9--10). Immobility time presented as a percentage of total time. (C) Forced swim test (n = 9). Immobility time presented as a percentage of total time. (D) Elevated plus maze test (n = 8--9). Representative heatmap of tracking movement and time in open arms (percentage of the total time). (E) Sucrose preference test (n = 8). Percentage of sucrose water intake. Data are means with SEM; Unpaired Student\'s t-test \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#\#*P* \< 0.0001 vs Non-stress Control; One-way ANOVA for CUMS, Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs CUMS vehicle treated.Fig. 2

3.2. CCFM1025 mitigated hypothalamic-pituitary-adrenal (HPA) axis hyperactivity-induced inflammation {#sec3.2}
----------------------------------------------------------------------------------------------------

The basal hypothalamus-released CRF ([Fig. 3](#fig3){ref-type="fig"}A, T ~(10)~ = 3.259, *P* = 0.009) and serum corticosterone ([Fig. 3](#fig3){ref-type="fig"}B, U = 3.0, *P* = 0.001) levels were elevated in chronically stressed mice. The expression of glucocorticoid receptor (GR) was significantly reduced ([Fig. 3](#fig3){ref-type="fig"}D, T ~(10)~ = 3.101, *P* = 0.011), while the level of mineralocorticoid receptor (MR) showed no statistical difference from the control group ([Fig. 3](#fig3){ref-type="fig"}C, T ~(10)~ = 1.111, *P* = 0.293). All of the HPA-axis related abnormalities were restored by treatment of CCFM1025 and fluoxetine ([Fig. 3](#fig3){ref-type="fig"}A, F ~(2,\ 15)~ = 10.38, *P*~*adj*~ = 0.002; [Fig. 3](#fig3){ref-type="fig"}B, F ~(2,\ 21)~ = 9.812, *P*~*adj*~ \< 0.001; [Fig. 3](#fig3){ref-type="fig"}D, F ~(2,\ 14)~ = 4.544, *P*~*adj*~ = 0.030). Hippocampal 5-*Htr1a* mRNA level was decreased in chronically stressed mice ([Fig. 3](#fig3){ref-type="fig"}E, T ~(10)~ = 2.677, *P* = 0.023) and both fluoxetine and CCFM105 could restore it (F ~(2,\ 15)~ = 30.69, *P*~*adj*~ \< 0.001). In addition, the hippocampal inflammatory cytokine IL-1β was significantly increased ([Fig. 3](#fig3){ref-type="fig"}G, T ~(10)~ = 2.277, *P* = 0.046), but CCFM1025 treatment could only reduce the hippocampal IL-6 levels ([Fig. 3](#fig3){ref-type="fig"}I, H = 7.45, *P*~*adj*~ = 0.026), whereas fluoxetine treatment showed no obvious anti-inflammatory effects. Gene expression of T-helper specific transcription factors was measured to evaluate the proportion of Th1, Th2, and Th17 cells. CCFM1025 treatment reversed stress-induced overexpression of *T-bet* ([Fig. 3](#fig3){ref-type="fig"}K, T ~(10)~ = 2.472, *P* = 0.033; F ~(2,\ 14)~ = 10.00, *P*~*adj*~ = 0.002) and *Ror-γt* ([Fig. 3](#fig3){ref-type="fig"}M, U = 2.5, *P* = 0.043; H = 8.036, *P*~*adj*~ = 0.015), but had no effect on *GATA3* ([Fig. 3](#fig3){ref-type="fig"}L, U = 1.0, *P* = 0.03; H = 0.845, *P*~*adj*~ \> 0.999). CCFM1025 also reduced circulating TNF-α ([Fig. 3](#fig3){ref-type="fig"}F, F ~(2,\ 15)~ = 6.146, *P*~*adj*~ = 0.011) concentration, while no statistical difference was observed in serum IL-1β, IL-6 and IL-17 concentration ([Supplemental Fig. S1](#appsec1){ref-type="sec"}).Fig. 3CCFM1025 alleviated HPA-axis hyperactivity and inflammation. (A) Hypothalamus corticotropin-releasing hormone (CRF) (n = 6). (B) Serum corticosterone levels (μg/L) (n = 8). (C) Transcript levels of mineralocorticoid receptor (*Nr3c2*) in the hippocampus (n = 6). (D) Transcript levels of the glucocorticoid receptor (*Nr3c1*) in the hippocampus (n = 5--6). (E) Transcript levels of serotonin receptors (*Htr1a*) in the hippocampus (n = 6). (F) Serum TNF-α levels (ng/L) (n = 6). (G-J) Hippocampal inflammatory cytokines levels (G- I, n = 6; J, n = 5). (K-M) Hippocampal T helper cell-specific transcription factors levels (mRNA) (K, n = 5--6; L, n = 4--6; M, n = 4--6). Data are means with SEM; Unpaired Student\'s t-test (or Mann Whitney test) \#*P* \< 0.05, \#\#*P* \< 0.01 vs Non-stress Control; One-way ANOVA (or Kruskal-Wallis test) for CUMS, Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 vs CUMS vehicle treated.Fig. 3

3.3. CCFM1025 regulated BDNF and c-Fos expression in brain {#sec3.3}
----------------------------------------------------------

In the CUMS group, pCREB was overexpressed in the prefrontal cortex (PFC) ([Fig. 4](#fig4){ref-type="fig"}A, T ~(10)~ = 4.964, *P* = 0.001), while the total CREB showed no statistical difference ([Fig. 4](#fig4){ref-type="fig"}A, T ~(10)~ = 0.918, *P* = 0.380; gel photo in [Supplemental Fig. S2](#appsec1){ref-type="sec"}). The downstream c-Fos was also overexpressed under chronic stress, at both the translation ([Fig. 4](#fig4){ref-type="fig"}B, T ~(4)~ = 8.332, *P* = 0.001; Representative sections of immuno-fluorescence staining are in [Supplemental Fig. S3](#appsec1){ref-type="sec"}) and transcription levels ([Fig. 4](#fig4){ref-type="fig"}C, T ~(10)~ = 3.139, *P* = 0.011). CCFM1025 and fluoxetine treatments down-regulated pCREB ([Fig. 4](#fig4){ref-type="fig"}A, F ~(2,\ 15)~ = 5.441, *P*~*adj*~ = 0.017) and accordingly normalized the expression of c-Fos ([Fig. 4](#fig4){ref-type="fig"}B, F ~(2,\ 6)~ = 10.90, *P*~*adj*~ = 0.010; [Fig. 4](#fig4){ref-type="fig"}C, F ~(2,\ 15)~ = 5.124, *P* = 0.020). Chronic stress significantly decreased hippocampal mature BDNF level ([Fig. 4](#fig4){ref-type="fig"}F, T ~(10)~ = 2.277, *P* = 0.046). In contrast to the alteration of mature BDNF, the level of proBDNF increased ([Fig. 4](#fig4){ref-type="fig"}E, T ~(4)~ = 8.332, *P* = 0.022), particularly in the hippocampal regions of the dentate gyrus (DG) and the CA3. CCFM1025 significantly normalized the balance of proBDNF/BDNF levels to that of controls ([Fig. 4](#fig4){ref-type="fig"}E and F ~(2,\ 6)~ = 18.80, *P*~*adj*~ = 0.003; [Fig. 4](#fig4){ref-type="fig"}F, F ~(2,\ 13)~ = 10.65, *P*~*adj*~ = 0.002).Fig. 4CCFM1025 treatment regulates the CREB-BDNF/c-Fos pathway. (A) p-CERB/CREB expression in prefrontal cortex (PFC) (n = 6). Representative western blots (three out of six samples) and quantification of band intensities (relative to the expression of GAPDH); (B) c-Fos levels in PFC (n = 3). Representative sections of immuno-fluorescence staining are in [Supplemental Fig. S3](#appsec1){ref-type="sec"} The transcript levels of *c-fos* in PFC (n = 6). (D) Representative immunohistochemical staining of proBDNF in the dorsal hippocampus. DG and CA3 regions are displayed below (E). The histogram indicates the proBDNF levels qualified by staining intensity (n = 3) (F) Mature BDNF (mBDNF) levels in the hippocampus (n = 5--6). Data are means with SEM; Unpaired Student\'s t-test \#*P* \< 0.05, \#\#\#*P* \< 0.001, \#\#\#\#*P* \< 0.0001 vs Non-stress Control; One-way ANOVA (or Kruskal-Wallis test) for CUMS, Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01 vs CUMS vehicle treated.Fig. 4

3.4. Stress-induced gut microbiota abnormalities were restored by CCFM1025 treatment {#sec3.4}
------------------------------------------------------------------------------------

α-diversity was significantly decreased in the chronically stressed group, as determined via Shannon ([Fig. 5](#fig5){ref-type="fig"}A, T ~(14)~ = 3.414, *P* = 0.004) and Simpson ([Fig. 5](#fig5){ref-type="fig"}B, T ~(14)~ = 3.074, *P* = 0.008) indices. CCFM1025 was able to maintain the α-diversity under chronic stress ([Fig. 5](#fig5){ref-type="fig"}A, F ~(2,\ 16)~ = 7.400, *P*~*adj*~ = 0.005; [Fig. 5](#fig5){ref-type="fig"}B, F ~(2,\ 16)~ = 6.768, *P*~*adj*~ = 0.007). A significant difference in β-diversity between the control and CUMS groups was revealed by the PCoA and perMANOVA ([Fig. 5](#fig5){ref-type="fig"}B, F = 7.088, *P* = 0.001; *P* ~Control\ vs\ CUMS~ = 0.003). The structure of gut microbiota in CCFM1025-and fluoxetine-treated group showed a trend of separation from the CUMS group ([Fig. 5](#fig5){ref-type="fig"}B, *P* ~CCFM1025\ vs\ CUMS~ = 0.002; *P* ~Fluoxetine\ vs\ CUMS~ = 0.003). CCFM1025 and fluoxetine treatment normalized the ratio of Actinobacteria: Proteobacteria ([Fig. 5](#fig5){ref-type="fig"}E, T ~(14)~ = 3.517, *P* = 0.009; F ~(2,\ 16)~ = 8.541, *P*~*adj*~ = 0.003) but failed to restore the ratio of Bacteroidetes: Firmicutes ([Fig. 5](#fig5){ref-type="fig"}F, T ~(14)~ = 3.729, *P* = 0.002; F ~(2,\ 16)~ = 5.624, *P*~*adj*~ = 0.991), which are two most abundant taxa in gut microbiota. Twelve genera were screened by LEfSe ([Fig. 5](#fig5){ref-type="fig"}G, [Supplemental Fig. S4](#appsec1){ref-type="sec"}), and six of them were significantly affected by both stress and CCFM1025 treatment ([Fig. 5](#fig5){ref-type="fig"}H-M). Using the phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt), seven pathways computed from KEGG were identified differential between CCFM1025 and CUMS group (Welch\'s-t test, *P* \< 0.001; [Fig. 5](#fig5){ref-type="fig"}N), among which the *arginine and proline metabolism* and *phenylalanine* and *tyrosine and tryptophan biosynthesis* pathways were significantly upregulated by CCFM1025.Fig. 5Effect of CCFM1025 treatment on gut microbial composition. (A-B) Microbial α-diversity, indicated by the Shannon and Simpson indices (n = 5--8 for each test). (C) Principal coordinates analysis. Contribution vectors (%) of the principal components are labeled on the axes. The difference between groups was analyzed by perMANOVA. (D) The abundance of taxa at the phylum level. The size and color of the circles respectively display the average abundance and coefficient of variance (CV) of the abundance. (E-F) The ratio of Actinobacteria: Proteobacteria and Bacteroidetes: Firmicutes. (G) Linear discriminant analysis (LDA) effect size (LEfSe). Differential taxa are labeled with tags and annotated in the right panel. Data were computed with an LDA score above 3.00 and *P* value below 0.05 for the factorial Kruskal-Wallis test. (H-M) The relative abundance of taxa found to be significantly altered by stress and CCFM1025 treatment (n = 5--8 for each test). (N) Differential microbial functions between CCFM1025 and depression groups. Metagenomic analysis was performed using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States), followed by annotation with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Statistical difference of the gene contents between the two groups is screened by Welch\'s-t test with *P* \< 0.0001. Data are means with SEM; Unpaired Student\'s t-test (or Mann Whitney test) \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#*P* \< 0.001 vs Non-stress Control; One-way ANOVA (or Kruskal-Wallis test) for CUMS, Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs CUMS vehicle treated.Fig. 5

3.5. *Bifidobacterium* spp. abundance correlated with intestinal 5-HTP levels {#sec3.5}
-----------------------------------------------------------------------------

*Bifidobacterium* and *Allobaculum* were identified as the top microbial contributors which shape the gut microbiota of chronically stressed mice ([Fig. 6](#fig6){ref-type="fig"}A). The distribution of *Bifidobacterium* species was further analyzed ([Fig. 6](#fig6){ref-type="fig"}B). The abundance of *Bifidobacterium pseudolongum* increased ([Fig. 6](#fig6){ref-type="fig"}C, T ~(11)~ = 2.722, *P* = 0.020) in chronically stressed mice. CCFM1025 treatment increased the abundance of *Bifidobacterium breve* ([Fig. 6](#fig6){ref-type="fig"}D, F ~(2,\ 13)~ = 4.041, *P*~*adj*~ = 0.043), and such competitive colonization reduced the *Bifidobacterium pseudolongum* abundance ([Fig. 6](#fig6){ref-type="fig"}D, H = 8.355, *P* = 0.011) (the relative abundance of all *Bifidobacterium* spp. was shown in [Supplemental Table S7](#appsec1){ref-type="sec"}). The effect of gut microbiota on the biosynthesis of 5-HTP was also investigated. CCFM1025 and fluoxetine normalized the reduced TPH1 ([Fig. 6](#fig6){ref-type="fig"}E, T ~(10)~ = 3.343, *P* = 0.008; F ~(2,\ 15)~ = 5.529, *P*~*adj*~ = 0.016; gel photo in [Supplemental Fig. S5](#appsec1){ref-type="sec"}) and 5-HTP ([Fig. 6](#fig6){ref-type="fig"}F, T ~(12)~ = 5.538, *P* = 0.001; F ~(2,\ 14)~ = 6.692, *P*~*adj*~ = 0.009) levels under stress. A network consisting of 40 nodes and 71 edges was constructed to determine the relationships among core microbial taxa and colonic 5-HTP levels ([Fig. 6](#fig6){ref-type="fig"}F). All edges connected two arguments of which the Spearman\'s coefficient was over 0.6 and the *P* value below 0.05. Colonic 5-HTP levels had a significant positive correlation with *B. breve* (r = 0.829), *Aerococcus* (r = 0.886), and *Oscillospira* (r = 0.943), but a negative correlation with *Akkermansia* (r = −0.943) and *B. pseudolongum* (r = −0.829), which confirmed that the gut microbiota and external excess of *B. breve* strains indeed affected the biosynthesis of 5-HTP in gut.Fig. 6*Bifidobacterium* spp. affect gut microbial functions. (A) Principal component analysis. Variables that contribute to the clustering are labeled by arrows. The acute angle between the two arrows indicated a positive correlation between the two variables (*P* \< 0.05). (B) Distribution of *Bifidobacterium* species in the *Bifidobacterium* genus. (C-D) The relative abundance of *Bifidobacterium pseudolongum* and *Bifidobacterium breve* (n = 4--7 each test). (E) TPH1 expression in the colon (n = 6). (F) 5-HTP levels in colon tissue (n = 5--7). Data are means with SEM; Unpaired Student\'s t-test \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#*P* \< 0.001 vs Non-stress Control; One-way ANOVA for CUMS (Chronic unpredictable mild stress), Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01 vs CUMS vehicle treated. (G) Network construction of gut microbial taxa and colon 5-HTP. Each connection between two nodes stands for a strong (Spearman\'s ρ \> 0.6) and a significant (*P* value \< 0.05) correlation. The size of each node is proportional to the number of connections. Blue lines represent positive correlation and the red lines represent a negative correlation. The color depth of the line represents the correlation strength. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 6

3.6. Gut microbial metabolites mediated 5-HTP facilitated the antidepressant-like effects of psychobiotics {#sec3.6}
----------------------------------------------------------------------------------------------------------

CCFM1025 improved the serum 5-HTP level ([Fig. 7](#fig7){ref-type="fig"}A, T ~(12)~ = 2.519, *P* = 0.027; H = 9.506, *P* = 0.006) and hippocampal 5-HT level ([Fig. 7](#fig7){ref-type="fig"}B, U = 4.0, *P* = 0.026; H = 11.92, *P* = 0.028). CCFM1025 showed no effect on improving the PFC 5-HT level ([Fig. 7](#fig7){ref-type="fig"}C, T ~(10)~ = 1.877, *P* = 0.09; F ~(2,\ 15)~ = 2.773, *P* = 0.095). Interestingly, a positive association between serum 5-HTP and brain 5-HT was demonstrated by Pearson\'s correlation coefficient ([Fig. 7](#fig7){ref-type="fig"}D, *P* \< 0.05). Besides, colonic 5-HTP and serum 5-HTP (*P* \< 0.05) concentration also negatively correlated with immobility time in TST and FST ([Fig. 7](#fig7){ref-type="fig"}D). Notably, tryptophan hydroxylases 2 (*Tph2*), the key enzyme controlling 5-HT biosynthesis in brain (mainly expressed in the brainstem) ([@bib43]), showed no difference among all groups ([Fig. 7](#fig7){ref-type="fig"}E, T ~(10)~ = 0.664, *P* = 0.522; H = 1.731, *P*~*adj*~ = 0.44). In addition, CCFM1025 and fluoxetine showed no effect on *slc6a4* gene expression in hippocampus ([Fig. 7](#fig7){ref-type="fig"}F, H = 4.940, *P*~*adj*~ = 0.081) and PFC ([Fig. 7](#fig7){ref-type="fig"}G and H = 1.979, *P*~*adj*~ = 0.391). Furthermore, we measured the SCFA levels in colonic contents. CCFM1025 extensively increased the concentration of SCFAs ([Fig. 7](#fig7){ref-type="fig"}H, acetate, F ~(2,\ 17)~ = 18.33, *P*~*adj*~ \< 0.001; propitiate, F ~(2,\ 16)~ = 26.57, *P*~*adj*~ \< 0.001; butyrate, F ~(2,\ 17)~ = 24.75, *P*~*adj*~ \< 0.001; isobutyric acid, F ~(2,\ 17)~ = 10.26, *P*~*adj*~ = 0.001; valeric acid, F ~(2,\ 17)~ = 9.803, *P*~*adj*~ = 0.002; isovaleric acid, F ~(2,\ 17)~ = 19.32, *P*~*adj*~ \< 0.001). Lastly, we confirmed the effect of CCFM1025 fermentation products and SCFAs in the biosynthesis of 5-HTP in an *in vitro* enterochromaffin cell model (RIN14B). After exposure to propionate and isobutyrate for 15 min, gene expression of *Tph1* was significantly upregulated ([Fig. 7](#fig7){ref-type="fig"}I, F ~(7,\ 40)~ = 13.23, *P*~*adj*~ \< 0.001). CCFM1025 also enhanced the expression of *Tph1* when the treatment was prolonged to 30 min ([Fig. 7](#fig7){ref-type="fig"}I, F ~(7,\ 40)~ = 5.537, *P*~*adj*~ \< 0.001).Fig. 7Gut derived 5-HTP mediated by microbial metabolites which facilitated the antidepressant-like effect of CCFM1025. (A) Serum 5-HTP levels (n = 7). (B-C) 5-HT levels in the hippocampus (n = 5--6) and PFC (n = 6). (D) Correlation analysis of peripheral 5-HTP levels, brain 5-HT levels, and behavioral performance. The color and size of the circle code for the level of correlation calculated by one-tailed Pearson\'s analyses (\**P* \< 0.05, \*\**P* \< 0.01). (E) Gene expression of tryptophan hydroxylase 2 (*tph2* mRNA) in the brainstem (n = 6). (F-G) Gene expression of the serotonin transporter (*slc6a4* mRNA) in the hippocampus (n = 5) and PFC (n = 6). (H) Colonic SCFAs levels (n = 6--8 for each test). Data are means with SEM; Unpaired Student\'s t-test (or Mann Whitney test) \#*P* \< 0.05 vs Non-stress Control; One-way ANOVA (or Kruskal-Wallis test) for CUMS, Fluoxetine- and CCFM1025-treated groups, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 vs CUMS vehicle treated. (I) Transcript levels of *Tph1* in RIN14B when exposure to SCFAs and CCFM1025 fermentation supernatant (n = 6). One-way ANOVA for all groups, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 vs HBSS.Fig. 7

4. Discussion {#sec4}
=============

Increasing evidence suggests that targeting the microbiota may be a novel strategy to counter the effects of stress ([@bib20]; [@bib40]). Here we show that a specific *Bifidobacterium breve* strain (CCFM1025) can counter many of the effects of chronic stress at a multitude of levels across the microbiota-gut-brain axis.

Similar to the clinical observations ([@bib24]; [@bib70]), mice exposed to chronic stress were also found to display alterations in microbial composition (dysbiosis) ([Fig. 5](#fig5){ref-type="fig"}). Although the stress-induced changes in α-diversity are restored by CCFM1025 treatment, a new microbial profile, one which was more similar to normal microbiota than that treated with fluoxetine, was formed ([Fig. 5](#fig5){ref-type="fig"}C). Interestingly, stress-induced alteration of some taxa was irreversible, the majority of which belonged to the Bacteroidetes and Firmicutes phyla. *Bifidobacterium* was the leading contributor characterizing the microbiota structure of chronically stressed mice ([Fig. 6](#fig6){ref-type="fig"}A), and the abundance of *Bifidobacterium* was significantly increased under chronic stress but normalized by both the probiotic and the drug. Since *Bifidobacterium* is the most abundant taxa in Actinobacteria, the phylum showed a similar trend with *Bifidobacterium*. Until now, only one clinical study has reported a reduction of *Bifidobacterium* in MDD patients. However, this study failed to control for gender and diet effects ([@bib1]). Some groups previously demonstrated an increased Actinobacteria abundance in MDD patients ([@bib27]; [@bib70]), which were consistent with our results. *Bifidobacterium* counts are commonly observed lower in a diseased status, such as with infection and irritable bowel syndrome ([@bib54]). It is intriguing that our observation was unconventional, but we believe the physiological role of bifidobacteria should be considered at the species level. Through further identification of *Bifidobacterium* spp., we confirmed the bloom of *Bifidobacterium* in depression involved *Bifidobacterium pseudolongum* specifically. Although *B. pseudolongum* has been described as one of the most predominant bifidobacteria in the murine intestine, its physiological function remains largely unknown ([@bib10]). It\'s worth noting that the abundance of *B. pseudolongum* negatively correlated with colonic 5-HTP levels while *B. breve* displayed the opposite effect ([Fig. 6](#fig6){ref-type="fig"}G). Moreover, the administration of a *B. breve* strain improved the metagenomic function of tryptophan biosynthesis, an important branch pathway acting as the precursor for the biosynthesis of 5-HTP and 5-HT ([Fig. 5](#fig5){ref-type="fig"}N). This evidence demonstrates that the competitive colonization of *B. breve* plays a key role in alleviating gastrointestinal and microbial abnormalities in depression. Our results outlined the *Bifidobacterium* composition in chronically stressed mice, for the first time, which proposes that the role of *Bifidobacterium* in stress and depression is not straightforward and should be explored at species level if possible.

Apart from *Bifidobacterium*, another five genus taxa were also normalized from the stress-induced dysbiosis ([Fig. 5](#fig5){ref-type="fig"}H, J-M), including *Allobaculum* and *Coprococcus* which are typical SCFA-producing bacteria. *Coprococcus* spp. have been shown to produce butyrate, propionate, and lactate as main fermentation products from non-digestible dietary polysaccharides ([@bib32]), whereas *Allobaculum* spp. produces acetate via the acetyl-CoA pathway, providing a substrate for butyrate synthesis ([@bib34]). The decrease of *Bacillus* was also reversed by CCFM1025. *Bacillus* spp. have been used as medicinal supplements for over 50 years, for their capacity to produce anti-pathogenic compounds ([@bib14]; [@bib60]). A recent clinical study indicated that oral *Bacillus coagulans* MTCC 5856 efficiently attenuated irritable bowel syndrome and depression symptoms in patients ([@bib42]). CCFM1025 also significantly increased the abundance of *Ruminococcus*. *Ruminococcus* spp. such as *R. obeum* with propanediol pathway was reported to produce propionate ([@bib41]). The alteration of these taxa causally increased the intestinal SCFA levels ([Fig. 7](#fig7){ref-type="fig"}H). SCFAs are well known as energy substrates and signaling molecules presenting a variety of distinct physiological effects, such as improving barrier function, maintaining immune homeostasis, and stimulating the secretion of gut peptides ([@bib36]; [@bib55]; [@bib69]). Our results demonstrated the potential capacity of propionate and isobutyrate to improve the 5-HTP levels through upregulating the *Tph1* expression *in vitro* ([Figs. 6](#fig6){ref-type="fig"}F and [7I](#fig7){ref-type="fig"}). As the key neurotransmitter which can cross the BBB, 5-HTP links the bidirectional communication between gut and brain, making it possible for the brain and gut to jointly maintain a host\'s health. Over 90% of the endogenous 5-HTP is produced by enterochromaffin cells using dietary L-tryptophan, and gut microbiota is essential during this process ([@bib2]; [@bib67]). Gastrointestinal derived 5-HTP (oral administration) has been demonstrated to enter the brain and participate in 5-HT synthesis ([@bib22]). Notably, the slow release of exogenous 5-HTP significantly delays the elimination of plasma 5-HTP, thus potentially maintaining consistently high precursor level for 5-HT synthesis and enhance the antidepressant-like effects of SSRI ([@bib25], [@bib26]). In stressed mice, CCFM1025 treatment increased the hippocampal 5-HT levels without significantly affecting the expression of *tph2* and *slc6a4* ([Fig. 7](#fig7){ref-type="fig"}B, E & F). This evidence may suggest that an extra-brain compensation pathway exists. It is tempting to speculate that it is the gut-derived 5-HTP that participates in the synthesis of brain 5-HT, because of the statistically positive correlation among gut 5-HTP, serum 5-HTP and brain 5-HT levels ([Fig. 7](#fig7){ref-type="fig"}D). This is the first time, to our knowledge, that we provide indirect evidence from both *in vivo* and *in vitro* studies that probiotics improve the 5-HTP biosynthesis of enterochromaffin cells via an SCFA-mediated way, and as such gut-derived 5-HTP may facilitate the improvement of brain 5-HT then show the antidepressant-like effects.

The mechanisms involved in stress-induced behavioral changes include HPA axis dysregulation and increased inflammation ([@bib51]). Here we show, as expected, that chronic stress impaired the negative feedback of corticosterone in the HPA axis by downregulating the glucocorticoid receptors ([Fig. 3](#fig3){ref-type="fig"}D). The alteration in glucocorticoid receptor gene expression can lead to glucocorticoid resistance and is also coincident with a high level of inflammation, consistent with previous reports ([@bib11]; [@bib15]; [@bib29]; [@bib48]; [@bib49]). Interestingly, CCFM1025 intervention normalized the stress-induced expression of brain *Nr3c1*, as well as serum proinflammatory cytokine measures and in turn, led to the alleviation of depression-related behaviors. However, more studies are needed to assess the relative causal contribution of the HPA axis and inflammation to the behavioral effects of CCFM1025.

In addition, pretreatment with CCFM1025 was able to counteract these effects of stress on key neuroplasticity related pathways. These include attenuating the pCREB-mediated overexpression of proBDNF and c-Fos, but increasing mBDNF levels ([Fig. 4](#fig4){ref-type="fig"}). proBDNF, the precursor of mature BDNF, binds to p75 neurotrophin receptor with high affinity, which triggers a long-term depression and neuronal apoptosis in the brain ([@bib37]; [@bib58]). However, the imbalance between BDNF/proBDNF in depression was still largely unknown. Clinical studies found that depression patients showed a decreased serum BDNF level, while the proBDNF was not affected, or even up-regulated ([@bib52]; [@bib68]; [@bib71]). Increased conversion of proBDNF to BDNF within the hippocampus was also observed in rats under an enriched living condition with less environmental stress, which in turn reduced their depression- and anxiety-like behaviors ([@bib8]).

There are several limitations that needed to be addressed. First, the present results were all generated from male mice. Since the prevalence of depression in humans is much greater in female individuals, future studies should assess the potential for antidepressant-like effects of CCFM1025 in female rodents before further confirmation in clinical trials. Second, it is still unclear which metabolites produced by CCFM1025 contribute to its antidepressant-like effect. A metabolomics-based analysis of CCFM1025 fermented products should be investigated. It is also helpful to investigate the gut-brain related metabolomics, for elucidating the metabolic kinetics of gut enterochromaffin cell-derived 5-HTP trafficking from the gut into the brain. At last, although we have shown a number of plausible mechanisms underpinning the behavioral effects of CCFM1025, future work is needed to prove the causality of these pathways and temporality of such effects.

In summary, the present study demonstrated a marked antidepressant-like effect of *Bifidobacterium breve* CCFM1025. The potential mechanisms involved may include the mitigation of HPA-axis hyperactivity and inflammation, up-regulation of BDNF coupled with down-regulation of c-Fos levels, enhancing the serotonergic system in both gut and brain, as well as the modification on gut microbial composition and metagenome. This study further supports the importance of targeting the microbiota-gut-brain axis in regulating mood disorder and offers a strategy for testing the potential psychobiotic basis for novel therapeutic strategies for depression.
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